AGP Picks
View all

LATAM Daily Brief: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on LATAM Daily Brief.

Press releases published on May 13, 2026

De startup a Nasdaq Stockholm: Alessandro Ciacchini alcanza un hito global con Maha Capital y KEO World
AMPP Brings Industry Voice to Capitol Hill as Infrastructure Policy Focus Shifts to Long-Term Performance
International Polo Tour® Makes Historic Return in Ecuador with the IPT BUGGATTI World Cup Invitational
Healthcare AI Startup ASTRID Adds Spanish Across Medical, Dental, and Veterinary AI Agents
Adsterra Explica Su Sistema Antifraude y Antimalware para Proteger a Anunciantes y Editores
Copa Holdings Reports First-Quarter Financial Results
Emerita Announces That the IBW Project Has Commenced the Public Consultation Phase for the Exploitation Permit Application
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Medicenna Announces the Launch of a Marketed Public Offering of Securities
US Critical Materials and Bayan Mining and Minerals Announce Strategic Collaboration to Advance Rare Earth Processing Capability Utilizing Colorado School of Mines Technology
XS.com Reconhecida como “Melhor Corretora de CFDs” em Evento da Rankia no Peru
Panoro Minerals Ltd. Announces Closing of Upsized Brokered LIFE Offering for Gross Proceeds of C$21,000,000
Noted Vaccine Researchers Uğur Şahin and Özlem Türeci Awarded Sabin Vaccine Institute’s Albert B. Sabin Gold Medal; Genomic Scientist Senjuti Saha of Bangladesh Receives Rising Star Award
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Lite Strategy Reports Fiscal 2026 Third Quarter Results
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

LATAM Daily Brief

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.